Akums Drugs and Pharmaceuticals Limited — Others, 18-07-2025: Shareholders meeting

Akums Drugs and Pharmaceuticals held its 21st Annual General Meeting, reflecting on its journey post-IPO and listing. The company highlighted a resilient financial year, marked by a landmark EUR 200 million CDMO contract and expansion of manufacturing capacity with new facilities. R&D investments totaling Rs 130 Cr yielded significant regulatory approvals. Strategic partnerships and ESG initiatives were also emphasized. Shareholders considered adopting FY24-25 financial statements, re-appointing a director, appointing auditors, ratifying cost auditor remuneration, and appointing an Independent Director.